Skip to main content
. 2022 Sep 20;328(11):1073–1084. doi: 10.1001/jama.2022.15632

Figure 2. Percentage of Patients Achieving IGA Success Over Time in DERMIS-1 and DERMIS-2.

Figure 2.

The primary end point for both studies was success on the Investigator Global Assessment (IGA) scale, defined as achievement of clear or almost clear status plus ≥2-grade improvement from baseline at 8 weeks.7 P < .001 for the difference at 8 weeks for both studies. Patients who completed the IGA at week 8 (±7 days) were considered completers. The percentage of patients who completed the 8-week study was 88.4% in DERMIS-1 and 89.4% in DERMIS-2. Observed percentages are presented. P values are based on analysis with imputation of missing data and stratification by pooled study sites, baseline IGA, and baseline intertriginous IGA. Whiskers represent 95% CIs.